Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00

Alto Neuroscience (NYSE:ANRO) had its target price raised by stock analysts at Chardan Capital from $15.00 to $30.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 80.67% from the company’s current price.

ANRO has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Jefferies Financial Group boosted their target price on Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. BTIG Research initiated coverage on Alto Neuroscience in a report on Monday, November 17th. They issued a “buy” rating and a $27.00 price objective for the company. Finally, Robert W. Baird upped their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $26.33.

Alto Neuroscience Price Performance

ANRO opened at $16.61 on Monday. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $20.91. The firm has a 50-day moving average of $14.89 and a 200 day moving average of $7.83. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The firm has a market cap of $515.92 million, a P/E ratio of -7.25 and a beta of 2.78.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. On average, research analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can bought a new position in Alto Neuroscience in the 2nd quarter worth about $25,000. Ground Swell Capital LLC purchased a new stake in shares of Alto Neuroscience in the second quarter worth about $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Alto Neuroscience in the second quarter worth about $33,000. AlphaCore Capital LLC boosted its position in shares of Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after acquiring an additional 10,000 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Alto Neuroscience during the first quarter valued at approximately $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.